Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The ...

Clinical Trials

Relapse Prevention Study in Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Iloperidone

First Posted Date: 2011-02-08

Last Posted Date: 2023-07-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 635

Registration Number: NCT01291511

Locations: 🇺🇦
Vanda Investigive Site, Kharkiv, Ukraine
🇺🇦
Vanda Investigative Site, Vinnytsya, Ukraine

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: tasimelteon

First Posted Date: 2011-01-06

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT01271387

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Phase 3

Active, not recruiting

Conditions: Non 24 Hour Sleep Wake Disorder

Interventions: Drug: tasimelteon

First Posted Date: 2010-10-11

Last Posted Date: 2024-04-03

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT01218789

Patient Registry of Blind Subjects With Sleep-related Problems

Recruiting

Conditions: Sleep-wake Disorder in Blind Individuals

Interventions: Other: Data collection on blindness and sleep problems

First Posted Date: 2010-09-06

Last Posted Date: 2020-06-24

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 10000

Registration Number: NCT01195558

Locations: 🇺🇸
Vanda Pharmaceuticals, Washington, District of Columbia, United States

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Phase 3

Completed

Conditions: Non-24-Hour Sleep-Wake Disorder

Interventions: Drug: tasimelteon
Drug: Placebo

First Posted Date: 2010-07-15

Last Posted Date: 2014-10-16

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT01163032

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
SDS Clinical Trials Inc., Orange, California, United States
🇺🇸
St. Johns Sleep Disorder Center - St. Johns Medical Plaza, Santa Monica, California, United States

and more 25 locations

VEC-162 Study in Adult Patients With Primary Insomnia

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: VEC-162 20 mg
Drug: VEC-162 50 mg
Drug: Placebo

First Posted Date: 2007-10-23

Last Posted Date: 2014-10-15

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 322

Registration Number: NCT00548340

Locations: 🇺🇸
Vanda Investigational Site, Dallas, Texas, United States

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Phase 2

Completed

Conditions: Circadian Rhythm Sleep Disorders

First Posted Date: 2007-06-25

Last Posted Date: 2014-08-26

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT00490945

Locations: 🇺🇸
Vanda Investigational Site, Detroit, Michigan, United States

VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness

Phase 2

Completed

Conditions: Excessive Somnolence

First Posted Date: 2007-04-30

Last Posted Date: 2007-11-02

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00467441

Locations: 🇫🇷
Vanda Investigational Site, Dijon, France

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Phase 3

Completed

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: 20 mg VEC-162
Drug: 100 mg VEC-162
Drug: 50 mg VEC-162

First Posted Date: 2006-02-13

Last Posted Date: 2014-10-15

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 411

Registration Number: NCT00291187

Locations: 🇺🇸
Vanda Investigational Site, Plano, Texas, United States

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Iloperidone
Drug: Placebo
Drug: Ziprasidone

First Posted Date: 2005-11-15

Last Posted Date: 2024-12-13

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 593

Registration Number: NCT00254202

Locations: 🇮🇳
Vanda Investigational Site, Chinawaltair, Visakha Patnam, India
🇮🇳
Vanda Investgational Site, Chennai, Tamilnadu, India

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy